395 related articles for article (PubMed ID: 26314515)
1. Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.
Pereira M; Jeyabalan J; Jørgensen CS; Hopkinson M; Al-Jazzar A; Roux JP; Chavassieux P; Orriss IR; Cleasby ME; Chenu C
Bone; 2015 Dec; 81():459-467. PubMed ID: 26314515
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
Lu N; Sun H; Yu J; Wang X; Liu D; Zhao L; Sun L; Zhao H; Tao B; Liu J
PLoS One; 2015; 10(7):e0132744. PubMed ID: 26177280
[TBL] [Abstract][Full Text] [Related]
3. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.
Yamada C; Yamada Y; Tsukiyama K; Yamada K; Udagawa N; Takahashi N; Tanaka K; Drucker DJ; Seino Y; Inagaki N
Endocrinology; 2008 Feb; 149(2):574-9. PubMed ID: 18039776
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
Li Z; Li S; Wang N; Xue P; Li Y
Biomed Pharmacother; 2020 Oct; 130():110523. PubMed ID: 32702632
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.
Wang N; Gao J; Jia M; Ma X; Lei Z; Da F; Yan F; Zhang H; Zhou Y; Li M; He G; Meng J; Luo X
Cell Physiol Biochem; 2017; 44(5):1696-1714. PubMed ID: 29216639
[TBL] [Abstract][Full Text] [Related]
6. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin Induces Bone Formation by Increasing Expression of Wnt10b in Osteoclasts in Ovariectomy-Induced Osteoporotic Rats.
Hsiao CY; Chen TH; Chu TH; Ting YN; Tsai PJ; Shyu JF
Front Endocrinol (Lausanne); 2020; 11():613. PubMed ID: 33013696
[TBL] [Abstract][Full Text] [Related]
8. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Mabilleau G; Pereira M; Chenu C
J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Luo G; Liu H; Lu H
Br J Clin Pharmacol; 2016 Jan; 81(1):78-88. PubMed ID: 27099876
[TBL] [Abstract][Full Text] [Related]
12. PTHrP-Derived Peptides Restore Bone Mass and Strength in Diabetic Mice: Additive Effect of Mechanical Loading.
Maycas M; McAndrews KA; Sato AY; Pellegrini GG; Brown DM; Allen MR; Plotkin LI; Gortazar AR; Esbrit P; Bellido T
J Bone Miner Res; 2017 Mar; 32(3):486-497. PubMed ID: 27683064
[TBL] [Abstract][Full Text] [Related]
13. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
14. Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin.
Meng J; Ma X; Wang N; Jia M; Bi L; Wang Y; Li M; Zhang H; Xue X; Hou Z; Zhou Y; Yu Z; He G; Luo X
Stem Cell Reports; 2016 Apr; 6(4):579-591. PubMed ID: 26947974
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
[TBL] [Abstract][Full Text] [Related]
16. Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats.
Xu B; He Y; Lu Y; Ren W; Shen J; Wu K; Xu K; Wu J; Hu Y
Life Sci; 2019 Jun; 226():47-56. PubMed ID: 30959027
[TBL] [Abstract][Full Text] [Related]
17. The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-
Shen WR; Kimura K; Ishida M; Sugisawa H; Kishikawa A; Shima K; Ogawa S; Qi J; Kitaura H
J Immunol Res; 2018; 2018():5783639. PubMed ID: 29725604
[TBL] [Abstract][Full Text] [Related]
18. Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.
Fulzele K; Dedic C; Lai F; Bouxsein M; Lotinun S; Baron R; Divieti Pajevic P
Bone; 2018 Dec; 117():138-148. PubMed ID: 30266511
[TBL] [Abstract][Full Text] [Related]
19. A quinoxaline-based compound ameliorates bone loss in ovariectomized mice.
Zhou Y; Xue X; Guo Y; Liu H; Hou Z; Chen Z; Wang N; Li F; Wang Y
Exp Biol Med (Maywood); 2021 Dec; 246(23):2502-2510. PubMed ID: 34308655
[TBL] [Abstract][Full Text] [Related]
20. Piezoelectric Microvibration Mitigates Estrogen Loss-Induced Osteoporosis and Promotes Piezo1, MicroRNA-29a, and Wnt3a Signaling in Osteoblasts.
Wu RW; Lian WS; Chen YS; Ko JY; Wang SY; Jahr H; Wang FS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
